Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Junker

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Immunology Letters|February 1, 1995
Functional role of CD26 on human B lymphocytesF Bühling, U Junker, D Reinhold, et al.
Cell Biology International|June 1, 1993
In patients with common variable immunodeficiency, interleukin-6 and expression of its receptor on B-cells are normalU Junker, B vd Heyden-Rynsch, C Diener, et al.
Der Urologe. Ausg. A|July 1, 1998
[Lymphocyte transformation test (LTT) as a model for evaluating cytokine-induced immunomodulation in renal cell carcinoma]T Steiner, U Junker, H Wunderlich, et al.
The Journal of Urology|May 1, 1997
Serum transforming growth factor-beta1 in patients with renal cell carcinomaH Wunderlich, T Steiner, U Junker, et al.
Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie|May 20, 2006
Design and evaluation of immunotoxicity studiesD R Roth, D Roman, P Ulrich, et al.
European Urology|April 18, 2001
Interferon-alpha suppresses the antiapoptotic effect of NF-kB and sensitizes renal cell carcinoma cells in vitro to chemotherapeutic drugsT Steiner, U Junker, B Henzgen, et al.
Schmerz (Berlin, Germany)|December 14, 2007
[Implementation of a standardized perioperative pain management concept in three hospitals of a consortium]P Saur, U Junker, P Gaus, et al.
Oncology Reports|February 13, 2003
Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptorsR Kaufmann, U Junker, M Schilli-Westermann, et al.
AIDS Research and Human Retroviruses|November 14, 1997
Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1U Junker, J Baker, C S Kalfoglou, et al.
Journal of Immunological Methods|February 14, 1998
A detailed protocol for the measurement of TGF-beta1 in human blood samplesD Reinhold, U Bank, F Bühling, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Immunology Letters|February 1, 1995
Functional role of CD26 on human B lymphocytesF Bühling, U Junker, D Reinhold, et al.
Cell Biology International|June 1, 1993
In patients with common variable immunodeficiency, interleukin-6 and expression of its receptor on B-cells are normalU Junker, B vd Heyden-Rynsch, C Diener, et al.
Der Urologe. Ausg. A|July 1, 1998
[Lymphocyte transformation test (LTT) as a model for evaluating cytokine-induced immunomodulation in renal cell carcinoma]T Steiner, U Junker, H Wunderlich, et al.
The Journal of Urology|May 1, 1997
Serum transforming growth factor-beta1 in patients with renal cell carcinomaH Wunderlich, T Steiner, U Junker, et al.
Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie|May 20, 2006
Design and evaluation of immunotoxicity studiesD R Roth, D Roman, P Ulrich, et al.
European Urology|April 18, 2001
Interferon-alpha suppresses the antiapoptotic effect of NF-kB and sensitizes renal cell carcinoma cells in vitro to chemotherapeutic drugsT Steiner, U Junker, B Henzgen, et al.
Schmerz (Berlin, Germany)|December 14, 2007
[Implementation of a standardized perioperative pain management concept in three hospitals of a consortium]P Saur, U Junker, P Gaus, et al.
Oncology Reports|February 13, 2003
Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptorsR Kaufmann, U Junker, M Schilli-Westermann, et al.
AIDS Research and Human Retroviruses|November 14, 1997
Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1U Junker, J Baker, C S Kalfoglou, et al.
Journal of Immunological Methods|February 14, 1998
A detailed protocol for the measurement of TGF-beta1 in human blood samplesD Reinhold, U Bank, F Bühling, et al.
Pageof 6